PNV21-001: A Phase I Study of a Personalized Multi-Peptide Neo-Antigen Vaccine in Breast Cancer, PD1/PD-L1 Inhibitor-Refractory Melanoma, and Pretreated Non-Small Cell Lung Cancer
Latest Information Update: 24 Mar 2025
At a glance
- Drugs Nivolumab (Primary) ; Peptide vaccines (Primary) ; Poly ICLC (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Malignant melanoma
- Focus Adverse reactions
- Acronyms PNV21-001
Most Recent Events
- 21 Mar 2025 Planned number of patients changed from 20 to 25.
- 23 Jul 2024 Planned End Date changed from 1 Nov 2025 to 1 Nov 2026.
- 23 Jul 2024 Planned primary completion date changed from 1 Nov 2024 to 1 Nov 2025.